Gaois

Search direction

Search mode

Filter results

Collections

13 results in 6 documents

  1. #293829

    - tástáil shaobhadh crómasóim smeara i mamaigh;

    - mammalian bone marrow chromosome aberration test;

    Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006

  2. #293834

    - tástáil shaobhadh crómasóim speirmeatógónaigh i mamaigh;

    - mammalian spermatogonial chromosome aberration test;

    Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006

  3. #293843

    - tástáil shaobhadh crómasóim in vitro i mamaigh;

    - in vitro mammalian chromosome aberration test;

    Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006

  4. #1959968

    ciallaíonn ‘cuid neamhchódaitheach de DNA’ réigiúin chrómasómacha nach sloinntear go géiniteach, i.e. nach eol go soláthraíonn siad aon airíonna feidhmiúla atá ag orgánach;

    "non-coding part of DNA" means chromosome regions not genetically expressed, i.e. not known to provide for any functional properties of an organism;

    Trade and Cooperation Agreement between the European Union and the European Atomic Energy Community, of the one part, and the United Kingdom of Great Britain and Northern Ireland, of the other part

  5. #2512377

    Meastar géin frithsheasmhachta frithmhiocróbaí a bheith intreach má tá sí suite ar chrómasóm in éagmais eilimint ghéiniteach shoghluaiste agus má tá sí ag tromlach thréithchineálacha fiáine an speicis chéanna;

    An antimicrobial resistance gene is considered intrinsic if it is located on a chromosome in the absence of mobile genetic element and shared by the majority of wild type strains of the same species;

    Commission Regulation (EU) 2022/1439 of 31 August 2022 amending Regulation (EU) No 283/2013 as regards the information to be submitted for active substances and the specific data requirements for micro-organisms (Text with EEA relevance)

  6. #2513969

    Meastar géin frithsheasmhachta frithmhiocróbaí a bheith intreach má tá sí suite ar chrómasóm in éagmais eilimint ghéiniteach shoghluaiste agus má tá sí ag tromlach thréithchineálacha fiáine an speicis chéanna;

    An antimicrobial resistance gene is considered intrinsic if it is located on a chromosome in the absence of mobile genetic element and shared by the majority of wild type strains of the same species;

    Commission Regulation (EU) 2022/1441 of 31 August 2022 amending Regulation (EU) No 546/2011 as regards specific uniform principles for evaluation and authorisation of plant protection products containing micro-organisms (Text with EEA relevance)

  7. #2749702

    Dá bhrí sin, na staidéir agus na sonraí ar thástálacha athshondais mhaighnéadaigh núicléach (“NMR”) chun aitheantas 2′-FL a chinneadh; an tuairisc ar na hanailísí ar sheicheamh géiniteach an tréithchineáil táirgthe ghéinmhodhnaithe 2′-FL; torthaí na n-anailísí chun neamhláithreacht cealla inmharthana den tréithchineál díorthach de Corynebacterium glutamicum ATCC 13032 a dheimhniú; an tástáil bhaictéarach ais-sócháin le 2′-FL, an tástáil saofa crómasóim in vitro le 2′-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 2′-FL; an tástáil micreanúicléis in vitro i limficít dhaonna le 2′-FL; agus, an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 2′-FL, ba cheart iad a chosaint i gcomhréir le hAirteagal 27(1) de Rialachán (AE) 2015/2283.

    Therefore, the studies and data on the nuclear magnetic resonance (‘NMR’) tests for the determination of the identity of 2′-FL; the genetic sequence analyses description of the genetically modified 2′-FL production strain; the results of analyses to confirm the absence of viable cells of the derivative strain of Corynebacterium glutamicum ATCC 13032; the bacterial reverse mutation test with 2′-FL, the in vitro chromosome aberration test with 2′-FL; the in vitro mammalian cell micronucleus test with 2′-FL; the in vitro human lymphocyte micronucleus test with 2′-FL; and, the 90-day oral toxicity study in rats with 2′-FL, should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283.

    Commission Implementing Regulation (EU) 2023/859 of 25 April 2023 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food 2’-Fucosyllactose (microbial source) to authorise its production by a derivative strain of Corynebacterium glutamicum ATCC 13032 (Text with EEA relevance)

  8. #2817594

    An 7 Deireadh Fómhair 2019 chuir an t-iarratasóir iarratas faoi bhráid an Choimisiúin freisin ar chosaint sonraí dílseánaigh, is é sin staidéar cógaschinéiteach i bhfrancaigh, tástáil bhaictéarach ais-sócháin, tástáil saofa crómasóim in vitro i mamaigh, tástáil micreanúicléis ar eiritricítí mamacha i lucha, staidéar 90 lá ar thocsaineacht ildáileog bhéil i bhfrancaigh, tástáil intuaslagthachta, tástáil micreanúicléis in vitro agus tástáil tocsaineachta ainsealaí aon bhliain amháin.

    On 7 October 2019, the applicant also made a request to the Commission for the protection of proprietary data, namely, pharmacokinetic study in rats, bacterial reverse mutation test, in vitro mammalian chromosome aberration test, mammalian erythrocyte micronucleus test in mice, repeated dose (90 days) oral toxicity study in rats, solubility test, in vitro micronucleus test and one year chronic toxicity test.

    Commission Implementing Regulation (EU) 2023/972 of 10 May 2023 authorising the placing on the market of aqueous ethanolic extract of Labisia pumila as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  9. #2817601

    Dhearbhaigh an t-iarratasóir go raibh cearta dílseánaigh agus eisiacha tagartha aige ar an staidéar cógaschinéiteach i bhfrancaigh, an tástáil bhaictéarach ais-sócháin, an tástáil saofa crómasóim in vitro i mamaigh, an tástáil micreanúicléis ar eiritricítí mamacha i lucha, an staidéar 90 lá ar thocsaineacht ildáileog bhéil i bhfrancaigh, an tástáil intuaslagthachta, an tástáil micreanúicléis in vitro agus an tástáil tocsaineachta ainsealaí aon bhliain amháin tráth a chuir sé an t-iarratas isteach, agus nach féidir le tríú páirtithe rochtain a fháil ar na sonraí sin ná iad a úsáid ná tagairt a dhéanamh dóibh go dleathach.

    The applicant declared that it held proprietary and exclusive rights of reference to the pharmacokinetic study in rats, bacterial reverse mutation test, in vitro mammalian chromosome aberration test, mammalian erythrocyte micronucleus test in mice, repeated dose (90 days) oral toxicity study in rats, solubility test, in vitro micronucleus test and one year chronic toxicity test at the time it submitted the application, and that third parties cannot lawfully access, use or refer to those data.

    Commission Implementing Regulation (EU) 2023/972 of 10 May 2023 authorising the placing on the market of aqueous ethanolic extract of Labisia pumila as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  10. #2817603

    Dá bhrí sin, an staidéar cógaschinéiteach i bhfrancaigh, an tástáil bhaictéarach ais-sócháin, an tástáil saofa crómasóim in vitro i mamaigh, an tástáil micreanúicléis ar eiritricítí mamacha i lucha, an staidéar 90 lá ar thocsaineacht ildáileog bhéil i bhfrancaigh, an tástáil intuaslagthachta, an tástáil micreanúicléis in vitro agus an tástáil tocsaineachta ainsealaí aon bhliain amháin, ba cheart iad a chosaint i gcomhréir le hAirteagal 27(1) de Rialachán (AE) 2015/2283.

    Therefore, pharmacokinetic study in rats, bacterial reverse mutation test, in vitro mammalian chromosome aberration test, mammalian erythrocyte micronucleus test in mice, repeated dose (90 days) oral toxicity study in rats, solubility test, in vitro micronucleus test and one year chronic toxicity test should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283.

    Commission Implementing Regulation (EU) 2023/972 of 10 May 2023 authorising the placing on the market of aqueous ethanolic extract of Labisia pumila as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

  11. #2749693

    An 7 Iúil 2020 chuir an t-iarratasóir iarraidh faoi bhráid an Choimisiúin freisin go gcosnófaí staidéir agus sonraí eolaíocha dílseánaigh maidir le tástálacha athshondais mhaighnéadaigh núicléach (“AMN”) chun aitheantas 2′-FL a chinneadh; tuairisc ar na hanailísí ar sheicheamh géiniteach an tréithchineáil táirgthe ghéinmhodhnaithe 2′-FL; torthaí na n-anailísí chun neamhláithreacht cealla inmharthana den tréithchineál díorthach de Corynebacterium glutamicum ATCC 13032 a dheimhniú; tástáil bhaictéarach ais-sócháin le 2′-FL; tástáil saofa crómasóim in vitro le 2′-FL; tástáil micreanúicléis in vitro i gcealla mamach le 2′-FL; tástáil micreanúicléis in vitro i limficít dhaonna le 2′-FL; staidéar ar ghéarthocsaineacht bhéil i bhfrancaigh; agus, staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 2′-FL, a cuireadh isteach mar thaca leis an iarratas.

    On 7 July 2020, the applicant also made a request to the Commission for the protection of proprietary scientific studies and data on nuclear magnetic resonance (‘NMR’) tests for the determination of the identity of 2′-FL; a genetic sequence analyses description of the genetically modified 2′-FL production strain; results of analyses to confirm the absence of viable cells of the derivative strain of Corynebacterium glutamicum ATCC 13032; a bacterial reverse mutation test with 2′-FL; an in vitro chromosome aberration test with 2′-FL; an in vitro mammalian cell micronucleus test with 2′-FL; an in vitro human lymphocyte micronucleus test with 2′-FL; an acute oral toxicity study in rats; and, a 90-day oral toxicity study in rats with 2′-FL, submitted in support of the application.

    Commission Implementing Regulation (EU) 2023/859 of 25 April 2023 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food 2’-Fucosyllactose (microbial source) to authorise its production by a derivative strain of Corynebacterium glutamicum ATCC 13032 (Text with EEA relevance)

  12. #2749698

    Sa tuairim eolaíoch uaidh, thug an tÚdarás dá aire go raibh a chonclúid maidir le sábháilteacht an bhia núíosaigh bunaithe ar staidéir agus sonraí eolaíocha ó thástálacha athshondais mhaighnéadaigh núicléach (“AMN”) chun aitheantas 2′-FL a chinneadh; an tuairisc ar na hanailísí ar sheicheamh géiniteach an tréithchineáil táirgthe ghéinmhodhnaithe 2′-FL; torthaí na n-anailísí chun neamhláithreacht cealla inmharthana den tréithchineál díorthach de Corynebacterium glutamicum ATCC 13032 a dheimhniú; an tástáil bhaictéarach ais-sócháin le 2′-FL; an tástáil saofa crómasóim in vitro le 2′-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 2′-FL, an tástáil micreanúicléis in vitro i limficít dhaonna le 2′-FL; agus an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 2′-FL, atá i gcomhad an iarratasóra, nach bhféadfadh sé measúnú a dhéanamh ar an mbia núíosach ná a chonclúid a bhaint amach dá n-uireasa.

    In its scientific opinion, the Authority noted that its conclusion on the safety of the novel food was based on scientific studies and data from the nuclear magnetic resonance (‘NMR’) tests for the determination of the identity of 2′-FL; the genetic sequence analyses description of the genetically modified 2′-FL production strain; the results of analyses to confirm the absence of viable cells of the derivative strain of Corynebacterium glutamicum ATCC 13032; the bacterial reverse mutation test with 2′-FL; the in vitro chromosome aberration test with 2′-FL; the in vitro mammalian cell micronucleus test with 2′-FL, the in vitro human lymphocyte micronucleus test with 2′-FL; and the 90-day oral toxicity study in rats with 2′-FL, contained in the applicant’s file, without which it could not have assessed the novel food and reached its conclusion.

    Commission Implementing Regulation (EU) 2023/859 of 25 April 2023 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food 2’-Fucosyllactose (microbial source) to authorise its production by a derivative strain of Corynebacterium glutamicum ATCC 13032 (Text with EEA relevance)

  13. #2749700

    Dhearbhaigh an t-iarratasóir go raibh cearta dílseánaigh agus eisiacha tagartha aige i leith na staidéar agus na sonraí eolaíocha ar thástálacha athshondais mhaighnéadaigh núicléach (“AMN”) chun aitheantas 2′-FL a chinneadh, an tuairisc ar sheicheamh géiniteach an tréithchineáil táirgthe ghéinmhodhnaithe 2′-FL; torthaí na n-anailísí chun neamhláithreacht cealla inmharthana den tréithchineál díorthach de Corynebacterium glutamicum ATCC 13032 a dheimhniú; an tástáil bhaictéarach ais-sócháin le 2′-FL; an tástáil saofa crómasóim in vitro le 2′-FL; an tástáil micreanúicléis in vitro i gcealla mamach le 2′-FL; an tástáil micreanúicléis in vitro i limficít dhaonna le 2′-FL; agus, an staidéar 90 lá ar thocsaineacht bhéil i bhfrancaigh le 2′-FL, faoin dlí náisiúnta an tráth a chuir sé an t-iarratas isteach, agus nach féidir le tríú páirtithe rochtain dhlíthiúil a fháil ar na sonraí ná na staidéir sin, iad a úsáid ná tagairt a dhéanamh dóibh.

    The applicant declared that they held proprietary and exclusive rights of reference to the scientific studies and data on the nuclear magnetic resonance (‘NMR’) tests for the determination of the identity of 2′-FL the genetic sequence analyses description of the genetically modified 2′-FL production strain; the results of analyses to confirm the absence of viable cells of the derivative strain of Corynebacterium glutamicum ATCC 13032; the bacterial reverse mutation test with 2′-FL; the in vitro chromosome aberration test with 2′-FL; the in vitro mammalian cell micronucleus test with 2′-FL; the in vitro human lymphocyte micronucleus test with 2′-FL; and, the 90-day oral toxicity study in rats with 2′-FL, under national law at the time they submitted the application and that third parties cannot lawfully access, use or refer to those data and studies.

    Commission Implementing Regulation (EU) 2023/859 of 25 April 2023 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food 2’-Fucosyllactose (microbial source) to authorise its production by a derivative strain of Corynebacterium glutamicum ATCC 13032 (Text with EEA relevance)